Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)

SHA:688091 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	386.65	44.01	649.53	914.76	710.38	110.43
Short-Term Investments	-	10.39	21.7	-	78.46	10.05
Trading Asset Securities	14.51	370.73	-	325.42	338.9	832.65
Cash & Short-Term Investments	401.16	425.13	671.23	1,240	1,128	953.13
Cash Growth	-17.35%	-36.66%	-45.88%	9.97%	18.32%	1774.41%
Accounts Receivable	165.87	130.19	49.27	143.15	42.44	4.1
Other Receivables	4.56	5.71	0.08	-	-	9.35
Receivables	170.43	135.9	49.35	143.15	42.44	13.46
Inventory	42.27	62.5	45.17	28.41	17.06	11.78
Prepaid Expenses	-	1.82	2.71	0.53	1.76	3.36
Other Current Assets	518.42	5.78	7.75	0.98	10.71	11.82
Total Current Assets	1,132	631.14	776.21	1,413	1,200	993.55
Property, Plant & Equipment	297.01	274.35	149.28	120.21	121.45	83.95
Long-Term Investments	-	569.9	467.77	21.01	20.32	105.82
Other Intangible Assets	30.3	28.76	8.36	8.58	8.79	9.01
Long-Term Deferred Tax Assets	13.71	10.85	7.62	5.65	1.84	6.07
Long-Term Deferred Charges	6.14	6.83	8.59	1.86	0.22	-
Other Long-Term Assets	104.32	5.24	30.16	2.81	2.25	2.16
Total Assets	1,584	1,527	1,448	1,573	1,355	1,201

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	66.09	26.15	23.33	31.83	13.58	0.74
Accrued Expenses	11.14	13.99	6.34	7.56	6.08	1.62
Short-Term Debt	-	-	-	44.03	-	16.75
Current Portion of Long-Term Debt	0.01	0.01	-	-	-	-
Current Income Taxes Payable	4.99	-	-	10.3	-	-
Current Unearned Revenue	2.21	1.58	4.38	1.11	0.12	-
Other Current Liabilities	5.12	27.12	5.39	9.16	10.08	2
Total Current Liabilities	89.56	68.85	39.45	103.98	29.86	21.1
Long-Term Debt	25	25	-	-	-	-
Long-Term Unearned Revenue	2.58	0.6	1.03	1.47	2.29	3.13
Long-Term Deferred Tax Liabilities	1.96	2.3	2.5	3.07	3.26	0.79
Total Liabilities	119.1	96.75	42.97	108.52	35.42	25.02

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	206.7	206.7	206.59	158.28	143.89	105.8
Additional Paid-In Capital	1,051	1,039	1,043	1,072	1,059	1,096
Retained Earnings	312.94	257.15	192.59	234.68	116.29	-26.56
Treasury Stock	-105.8	-72.24	-37.24	-	-	-
Shareholders' Equity	1,465	1,430	1,405	1,465	1,319	1,176
Total Liabilities & Equity	1,584	1,527	1,448	1,573	1,355	1,201

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	25.01	25.01	-	44.03	-	16.75
Net Cash (Debt)	376.15	400.12	671.23	1,196	1,128	936.38
Net Cash Growth	-22.51%	-40.39%	-43.88%	6.07%	20.44%	1867.20%
Net Cash Per Share	1.84	1.98	2.89	7.55	5.47	6.02
Filing Date Shares Outstanding	196.89	204.8	205.31	205.76	205.76	205.76
Total Common Shares Outstanding	196.89	204.8	205.31	205.76	205.76	205.76
Working Capital	1,043	562.29	736.76	1,309	1,170	972.45
Book Value Per Share	7.44	6.98	6.84	7.12	6.41	5.71
Tangible Book Value	1,434	1,402	1,397	1,456	1,310	1,167
Tangible Book Value Per Share	7.28	6.84	6.80	7.08	6.37	5.67
Buildings	-	80.55	80.55	80.55	80.55	80.55
Machinery	-	101.14	81.55	76.29	35.23	29.38
Construction In Progress	-	156.51	39.49	4.81	39.44	1.58

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error